Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) will release its second quarter 2026 financial results before U.S. market open on Tuesday, August 11, 2026, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
Investors can access the live webcast via Fennec’s website under Investors & Media > News & Events/Event Calendar, or through the provided webcast and participant registration links. A replay will be archived on the company’s site for 30 days. Fennec is a commercial-stage specialty pharmaceutical company focused on PEDMARK/PEDMARQSI, approved in the U.S., EU and U.K. to reduce the risk of platinum-induced ototoxicity in cancer patients, with an exclusive commercialization agreement with Norgine in Europe, the U.K., Australia and New Zealand and patent protection to 2039.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Net Selling was recorded across the last 90 days, while short positioning was categorized as low. Ag...
Analysis
Net Selling was recorded across the last 90 days, while short positioning was categorized as low. Against this 2Q26 reporting-date notice, the platform context highlights insider activity; the reported results remain the material follow-up.
Scheduled full-year and Q4 2025 results; shares recorded a negative 24-hour reaction afterward.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The two prior earnings-date announcements were followed by negative 24-hour reactions, averaging -3.82%.
Key Terms
ototoxicity, cisplatin-based chemotherapy, orphan drug exclusivity, pediatric use marketing authorization, +1 more
5 terms
ototoxicitymedical
"committed to the fight against ototoxicity in cancer patients"
Ototoxicity is damage to the inner ear caused by certain drugs or chemicals that can impair hearing and balance, ranging from temporary ringing to permanent hearing loss. Investors should care because ototoxic effects can limit a medical product’s marketability, trigger stricter safety testing, slow approvals, increase legal and treatment costs, and hurt sales—similar to a car defect that makes a model unsafe and forces recalls or redesigns.
cisplatin-based chemotherapymedical
"cancer patients who receive cisplatin-based chemotherapy"
A chemotherapy approach that uses the drug cisplatin, a platinum-containing compound, to kill cancer cells by damaging their DNA; think of it as using a corrosive agent that prevents faulty machinery from running. It matters to investors because cisplatin-based regimens affect drug sales, hospital treatment patterns, regulatory approvals, trial results and payer decisions, and their effectiveness and side effects can influence market demand for alternative therapies or supportive care products.
orphan drug exclusivityregulatory
"PEDMARK has received Orphan Drug Exclusivity in the U.S."
A regulatory right that gives a drugmaker sole approval to market a medicine for a specific rare disease for a set number of years, during which the regulator will not approve the same medicine from competitors for that same use. For investors, this is like a temporary exclusive sales permit that can protect revenue and justify higher valuation because it reduces near‑term competition and helps the company recover development costs and capture market share.
pediatric use marketing authorizationregulatory
"PEDMARQSI has received Pediatric Use Marketing Authorization in Europe"
A pediatric use marketing authorization is a regulatory approval that allows a drug or medical product to be sold and labeled specifically for use in children after authorities review pediatric safety, dosing and effectiveness data. It matters to investors because it opens a separate market segment, can change sales forecasts and regulatory risk, and may affect exclusivity or competition much like obtaining a new license to serve an additional group of customers.
exclusive licensing agreementfinancial
"entered into an exclusive licensing agreement under which Norgine"
An exclusive licensing agreement is a legal deal where the owner of an asset—like a drug formula, technology, or brand—gives one other party the sole right to use, sell, or develop that asset in a defined territory or field. For investors, exclusivity can act like a temporary monopoly: it can boost revenue and competitive edge by preventing rivals from using the same asset, but it also concentrates risk on the licensee’s success and the terms of payments or milestones.
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
Investors: Robert Andrade Chief Financial Officer Fennec Pharmaceuticals Inc. +1 919-246-5299
Corporate and Media: Lindsay Rocco Elixir Health Public Relations +1 862-596-1304 lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (NASDAQ: FENC) report its Q2 2026 financial results?
Fennec Pharmaceuticals plans to report its Q2 2026 financial results on Tuesday, August 11, 2026, before U.S. markets open. According to Fennec, management will then host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial and business results.
How can investors listen to Fennec Pharmaceuticals’ Q2 2026 earnings call on August 11, 2026?
Investors can listen to Fennec’s Q2 2026 earnings call via live webcast at 8:30 a.m. ET on August 11, 2026. According to Fennec, access is through www.fennecpharma.com under Investors & Media > News & Events/Event Calendar, with a 30-day replay available.
What does Fennec Pharmaceuticals (FENC) do and what is PEDMARK/PEDMARQSI?
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on preventing ototoxicity in cancer patients receiving cisplatin-based chemotherapy. According to Fennec, its product PEDMARK (PEDMARQSI in Europe and U.K.) is approved to reduce the risk of platinum-induced ototoxicity and is commercially available in multiple countries.
What regulatory approvals has Fennec’s PEDMARK/PEDMARQSI received as of 2026?
PEDMARK received FDA approval in September 2022, and PEDMARQSI obtained European Commission approval in June 2023 and U.K. approval in October 2023. According to Fennec, the product has U.S. Orphan Drug Exclusivity and European Pediatric Use Marketing Authorization with data and market protection.
What is Fennec Pharmaceuticals’ agreement with Norgine for PEDMARQSI commercialization?
In March 2024, Fennec entered an exclusive licensing agreement with Norgine Pharmaceuticals to commercialize PEDMARQSI in Europe, the U.K., Australia and New Zealand. According to Fennec, Norgine is a specialist pharmaceutical company and PEDMARQSI is now commercially available in multiple countries.
How long is patent protection for Fennec Pharmaceuticals’ PEDMARK product?
Fennec reports that patents provide protection for PEDMARK until 2039 in the U.S. and internationally. According to Fennec, this patent term complements U.S. Orphan Drug Exclusivity and European Pediatric Use Marketing Authorization, supporting long-term commercialization of PEDMARK/PEDMARQSI across multiple regions.
